A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Endometrial Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; TNBC – Triple-Negative Breast Cancer; Triple Negative Breast Cancer; Cholangiocarcinoma; Bile Duct Cancer; Colon Cancer; Colon Cancer Stage; Colon Neoplasm; Colon Adenocarcinoma; Colon Rectal Cancer; Colon Cancer Liver Metastasis; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic; Colorectal Cancer Stage IV; Rectum Cancer; Rectum Neoplasm; Rectum Carcinoma; Rectal Cancer; Rectal Neoplasms; Rectal Adenocarcinoma; Rectal Cancer Stage; Rectal Cancer Metastatic; Rectal Cancer Stage III; Esophagus Cancer; Esophageal Cancer; Esophageal Neoplasms; Gastric Cancer Stage; Breast Cancer; Breast Neoplasm; Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer Stage; Breast Cancer Metastatic; Breast Cancer Invasive; Triple Negative Breast Neoplasms; Intrahepatic Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma Recurrent; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Ovary Cancer; Ovary Neoplasm; Ovary Disease; Ovary Metastasis; Ovarian Diseases; Ovarian Cancer Stage; Ovarian Epithelial Cancer; Ovarian Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Neoplasm Epithelial; Ovarian Cancer Recurrent; Endometrial Diseases; Endometrial Adenocarcinoma; Endometrial Carcinosarcoma; Endometrial Clear Cell Adenocarcinoma; Endometrioid Adenocarcinoma; Endometrial Neoplasms; Endometrial Cancer Recurrent; Endometrioid Tumor; Fallopian Tube Cancer; Peritoneal Cancer
Intervention: Drug: ELU001
Sponsor: Elucida Oncology
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.